Moomoo AI 已提取核心信息
Cybin Inc., a clinical-stage biopharmaceutical company, announced on February 7, 2024, that it has been granted two additional patents in Japan, enhancing its intellectual property portfolio for its DMT program. The patents, expected to last until at least 2040 and 2041, cover synthesis methods and injectable formulations for DMT and deuterated DMT, which are in development for treating Generalized Anxiety Disorder (GAD). CEO Doug Drysdale highlighted the strategic importance of these patents in one of the world's largest pharmaceutical markets. The company also reported progress on its investigational new drug, CYB004, with the U.S. FDA clearing its application, allowing Phase 2a studies to commence in Q1 2024. Cybin's research pipeline includes other investigational psychedelic-based compounds for mental health disorders, with CYB003 and CYB004 being developed for major depressive disorder and GAD, respectively. Cybin operates internationally with a focus on revolutionizing mental healthcare through psychedelic-based therapeutics.
Cybin Inc., a clinical-stage biopharmaceutical company, announced on February 7, 2024, that it has been granted two additional patents in Japan, enhancing its intellectual property portfolio for its DMT program. The patents, expected to last until at least 2040 and 2041, cover synthesis methods and injectable formulations for DMT and deuterated DMT, which are in development for treating Generalized Anxiety Disorder (GAD). CEO Doug Drysdale highlighted the strategic importance of these patents in one of the world's largest pharmaceutical markets. The company also reported progress on its investigational new drug, CYB004, with the U.S. FDA clearing its application, allowing Phase 2a studies to commence in Q1 2024. Cybin's research pipeline includes other investigational psychedelic-based compounds for mental health disorders, with CYB003 and CYB004 being developed for major depressive disorder and GAD, respectively. Cybin operates internationally with a focus on revolutionizing mental healthcare through psychedelic-based therapeutics.
处于临床阶段的生物制药公司Cybin Inc. 于2024年2月7日宣布，它已在日本获得另外两项专利，从而增强了其DMT计划的知识产权组合。这些专利预计将至少持续到2040年和2041年，涵盖DMT和Deuterated DMT的合成方法和注射制剂，这些制剂正在开发中，用于治疗广泛性焦虑症（GAD）。首席执行官道格·德赖斯代尔强调了这些专利在全球最大的制药市场之一中的战略重要性。该公司还报告了其研究性新药 CYB004 的进展，美国食品药品管理局批准了其申请，允许在2024年第一季度开始2a期研究。Cybin的研究渠道包括其他用于治疗精神健康障碍的研究性迷幻药化合物，CYB003 和 CYB004 分别正在开发用于重度抑郁症和GAD。Cybin在国际上开展业务，专注于通过基于迷幻药的疗法彻底改变心理保健。
处于临床阶段的生物制药公司Cybin Inc. 于2024年2月7日宣布，它已在日本获得另外两项专利，从而增强了其DMT计划的知识产权组合。这些专利预计将至少持续到2040年和2041年，涵盖DMT和Deuterated DMT的合成方法和注射制剂，这些制剂正在开发中，用于治疗广泛性焦虑症（GAD）。首席执行官道格·德赖斯代尔强调了这些专利在全球最大的制药市场之一中的战略重要性。该公司还报告了其研究性新药 CYB004 的进展，美国食品药品管理局批准了其申请，允许在2024年第一季度开始2a期研究。Cybin的研究渠道包括其他用于治疗精神健康障碍的研究性迷幻药化合物，CYB003 和 CYB004 分别正在开发用于重度抑郁症和GAD。Cybin在国际上开展业务，专注于通过基于迷幻药的疗法彻底改变心理保健。
有用
没用